FKBP12 PROTAC dTAG-13 dTAG-13|cas:2064175-41-1|西域试剂

FKBP12 PROTAC dTAG-13 dTAG-13,99.75%

产品编号：Bellancom-114421| CAS NO：2064175-41-1| 分子式：C₅₇H₆₈N₄O₁₅| 分子量：1049.17

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-114421		￥5500.00	杭州北京（现货）
Bellancom-114421		￥8800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

FKBP12 PROTAC dTAG-13 dTAG-13

产品介绍

FKBP12 PROTAC dTAG-13 (dTAG-13) 是一种基于 PROTAC 的双功能降解剂，可降解 FKBP12^F36V。FKBP12 PROTAC dTAG-13 有效地接合 FKBP12^F36V 和 CRBN，从而选择性地降解 FKBP12^F36V。

生物活性

FKBP12 PROTAC dTAG-13 (dTAG-13), a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12^F36V with expression of FKBP12F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-13 effectively engages FKBP12^F36V and CRBN, thereby selectively degrading FKBP12^F36V.

体外研究

TAG-13 (1-1000 nM; 4 hours; 293FT^WT cells) treatment potently reduces FKBP12^F36V-Nluc levels in 293FT^WT cell, indicating the requirement of CRBN for the observed effects.
Treatment of MV4;11 cells expressing BRD4(short)-FKBP12^F36V with dTAG-13 leads to robust degradation of BRD4. dTAG-13 treatment leads to rapid degradation of BRD4 within one hou. dTAG-13 treatment leads to rapid and potent degradation of the BRD4 fusion chimera in the heterozygous and homozygous knock-in clones, with no effect on endogenous FKBP12^WT.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	293FT^WT cells
Concentration:	1 nM, 10 nM, 100 nM, 1000 nM
Incubation Time:	4 hours
Result:	Potently reduced FKBP12^F36V-Nluc levels in 293FT^WT cell.

体内研究
(In Vivo)

Following bone marrow engraftment of MV4;11 cells expressing luc-FKBP12F36V in mice, the bioluminescent signal after vehicle or dTAG-13 administration is monitored. A significant, rapid, and durable effect on bioluminescent signal is observed four hours after dTAG-13 administration, indicating effective degradation of luc-FKBP12F36V. Twenty-eight hours following the final treatment, the recovery of cellular bioluminescence to levels comparable between vehicle and dTAG-13 treatment groups is observed.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 180 mg/mL (171.56 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.9531 mL	4.7657 mL	9.5313 mL
5 mM	0.1906 mL	0.9531 mL	1.9063 mL
10 mM	0.0953 mL	0.4766 mL	0.9531 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式